PT  - JOURNAL ARTICLE
AU  - Jie Lu
AU  - Yuwei He
AU  - Robert Terkeltaub
AU  - Mingshu Sun
AU  - Zijing Ran
AU  - Xinmiao Xu
AU  - Can Wang
AU  - Xinde Li
AU  - Shuhui Hu
AU  - Xiaomei Xue
AU  - Fei Yan
AU  - Hui Zhang
AU  - Huiyong Yin
AU  - Yongyong Shi
AU  - Nicola Dalbeth
AU  - Changgui Li
TI  - Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination
AID  - 10.1136/annrheumdis-2022-222199
DP  - 2022 Aug 01
TA  - Annals of the Rheumatic Diseases
PG  - 1189--1193
VI  - 81
IP  - 8
4099  - http://ard.bmj.com/content/81/8/1189.short
4100  - http://ard.bmj.com/content/81/8/1189.full
SO  - Ann Rheum Dis2022 Aug 01; 81
AB  - Objectives COVID-19 vaccination often triggers a constellation of transitory inflammatory symptoms. Gout is associated with several comorbidities linked to poor outcomes in COVID-19, and gout flares can be triggered by some vaccinations. We analysed the risk of gout flares in the first 3 months after COVID-19 vaccination with inactivated virus, and whether colchicine can prevent gout flares following post-COVID-19 vaccination.Methods A clinical delivery population-based cross-sectional study was conducted in the Gout Clinic at the Affiliated Hospital of Qingdao University between February and October 2021. Study participants were selected using a systematic random sampling technique among follow-up patients with gout. We collected data, including vaccinations and potential risk factors, using a combination of interviews, health QR codes and medical records. Logistic regression was used to adjust for covariates.Results We enrolled 549 gout participants (median age 39 years, 84.2% vaccinated). For the 462 patients who received COVID-19 vaccine, 203 (43.9%) developed at least one gout flare in the 3 months after vaccination. Most of these flares were experienced within 1 month after the first (99/119 (83.2%)) or second (70/115 (60.9%)) dose of vaccine. Compared with unvaccinated participants, COVID-19 vaccination was associated with higher odds of gout flare within 3 months (adjusted OR 6.02; 95% CI 3.00 to 12.08). Colchicine use was associated with 47% less likelihood of postvaccine gout flare.Conclusion COVID-19 vaccination was associated with increased odds of gout flare, which developed mainly in month 1 after each vaccine dose, and was negatively associated with colchicine prophylaxis.Data are available on reasonable request. Not applicable.